Author: IPRO

The LACE index identifies patients that are at risk for readmission or death within thirty days of discharge. It incorporates four parameters.

The SHARE Approach: Essential Steps of Shared Decision-Making outlines five steps health care professionals can take to ensure they are effectively implementing shared decision making with patients during clinical encounters.

These are the slides from the presentation on March 2, 2023 featuring Julia Venanzi from CMS and Christine Cordero from the Joint Commission.

An on-line instructional webinar created in collaboration with IPRO QIN-QIO, the University at Buffalo, and the NYS Department of Health Bureau of Narcotic Enforcement can be accessed at the link above.

Prescribers and pharmacists who work or live in DC, DE, CT, MA, MD, ME, NH, NJ, NY, OH, RI, VT can earn 1.0 hour of free ACCME or ACPE continuing education for completing this program by using this code when prompted: qinub23.

It is available June 15, 2023, through June 12, 2025, and covers a variety of topics associated with the New York State Prescription Monitoring Program Registry (PMP) for controlled substances, including the use of the PMP registry search, use of the PMP Data Collection Tool, and interstate data sharing.

The purpose of this guide is improvement of cross-setting management of high risk medications (opioids, anticoagulants, and diabetes medications) during transitions of care to prevent adverse drug events and subsequently reduce emergency department visits, hospitalizations, and readmissions.

How can the Essential Communication Elements tools be utilized?

• Provide the fundamental communication criteria necessary for the proper transition of care related to pain medications, anticoagulants, and diabetes medications.
• Evaluate your facility practices regarding communication of requisite medication‐related elements to subsequent providers.
• Identify opportunities for system improvements.

Webpage to access the web-based, Apple App Store, and Google Play versions of the Clinician CKD Screening app and the patient-centered Kidney Choices app. IPRO’s Clinician CKD Screening and Patient-Centered Kidney Choices apps were designed to:
-Help identify CKD early in at-risk patients and to help manage CKD
-To help delay progression
-To provide kidney replacement information for patients whose CKD has progressed to kidney failure.

Webpage for the MAPPP app. Provides links to web-based, Apple App Store and Google Play versions of MAPPP app along with multiple patient education resources directly related to peri-procedural anticoagulant interruption. Surgery and invasive medical interventions increase the risk of bleeding, while withholding anticoagulants increases the risk of thrombosis due to the underlying condition(s) for which anticoagulation was originally prescribed. The clinical team must therefore balance these competing risks and make educated decisions regarding the decision to interrupt oral anticoagulation for a medical procedure and, if interrupted, whether to “bridge” anticoagulation with injectable anticoagulants, such as low molecular weight heparin (LMWH) in warfarin treated patients.

This guide is intended to:

Assist clinicians in the simultaneous evaluation of procedure-related bleeding risk and underlying risk of thrombosis
Guide decisions regarding the interruption of anticoagulation and the use of anticoagulant “bridging”
Provide detailed guidance for drug dosing and laboratory monitoring in the peri-procedural period
Encourage clear communication between clinicians involved in prescribing anticoagulants and performing invasive procedures

Complete the Opioid and Pain Management Best Practice Assessment.

The Opioid and Pain Management Best Practice Assessment was adapted from the CDC’s document: Quality Improvement and Care Coordination: Implementing the CDC Guideline for Prescribing Opioids for Chronic Pain. Our assessment contains 22 questions within 12 best practice recommendation areas with a Likert scale response range of whether the best practice is performed Very Frequently, Frequently, Occasionally, Rarely or Never. It is used with hospitals, nursing homes, home healthcare services, and primary care practices and is deployed quarterly after the initial response for serial assessment of improvement.

Use with Quality Improvement and Care Coordination: Implementing the CDC Guideline for Prescribing Opioids for Chronic Pain document and the Opioid and Pain Management Best Practice Aggregate Results Dashboard.

For more information see our website:

Complete the Opioid & Pain Management Self-Assessment

https://www.cdc.gov/opioids/healthcare-admins/pdf/Quality-Improvement-Care-Coordination-508.pdf

Use with the Opioid and Pain Management Best Practice Assessment and the Quality Improvement and Care Coordination: Implementing the CDC Guideline for Prescribing Opioids for Chronic Pain document.

The Opioid and Pain Management Best Practice Assessment Aggregate Results Dashboard shows baseline and quarterly results aggregated by all care settings, hospital, nursing home, home healthcare and primary care.

For questions or additional information about this Dashboard, please email Anne Myrka, RPh, MAT, amyrka@ipro.org .

This resource provides plain language information on medication safety for older adults.

Buprenorphine for Pain: A Transition Guide from Full Agonist Opioid Prescriptions is a tool intended to aid clinicians in switching patients off of full opioid agonists to buprenorphine, a partial mixed opioid agonist for pain management.

The information presented in this document should not be considered medical advice and is not a substitute for individualized patient or client care and treatment decisions.

The Buprenorphine Resource Guide is a resource that contains the various FDA-approved formulations of buprenorphine for Opioid Use Disorder and pain management. This resource guide also includes a brief history of buprenorphine and explains its analgesic effects.

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.